WO2000059488A3 - Enhanced tissue and subcellular delivery of vitamin e compounds - Google Patents

Enhanced tissue and subcellular delivery of vitamin e compounds Download PDF

Info

Publication number
WO2000059488A3
WO2000059488A3 PCT/US2000/008524 US0008524W WO0059488A3 WO 2000059488 A3 WO2000059488 A3 WO 2000059488A3 US 0008524 W US0008524 W US 0008524W WO 0059488 A3 WO0059488 A3 WO 0059488A3
Authority
WO
WIPO (PCT)
Prior art keywords
vitamin
compounds
antioxidant
enhanced tissue
mitochondria
Prior art date
Application number
PCT/US2000/008524
Other languages
French (fr)
Other versions
WO2000059488A2 (en
Inventor
Mark Fariss
Original Assignee
Univ Washington
Mark Fariss
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Washington, Mark Fariss filed Critical Univ Washington
Priority to EP00919928A priority Critical patent/EP1169033A2/en
Priority to AU40537/00A priority patent/AU4053700A/en
Priority to CA002366884A priority patent/CA2366884A1/en
Publication of WO2000059488A2 publication Critical patent/WO2000059488A2/en
Publication of WO2000059488A3 publication Critical patent/WO2000059488A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention provides a method for enhancing the delivery of antioxidant Vitamin E compounds to tissues, cells and subcellular sites (both in vivo and in vitro) and in particular to mitochondria, thereby increasing the antioxidative capacity of mitochondria. The Vitamin E compounds that are administered may be cleaved by cellular esterases to release antioxidant α-T, β-T, η-T, and/or δ-T. Further, the administration of Vitamin E compounds may have a coordinate action with respect to treating tumors in that the intact, uncleaved form of the Vitamin E compound has antitumor activity while the cleaved form exerts antioxidant effects.
PCT/US2000/008524 1999-04-02 2000-03-31 Enhanced tissue and subcellular delivery of vitamin e compounds WO2000059488A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP00919928A EP1169033A2 (en) 1999-04-02 2000-03-31 Enhanced tissue and subcellular delivery of vitamin e compounds
AU40537/00A AU4053700A (en) 1999-04-02 2000-03-31 Enhanced tissue and subcellular delivery of vitamin e compounds
CA002366884A CA2366884A1 (en) 1999-04-02 2000-03-31 Enhanced tissue and subcellular delivery of vitamin e compounds

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12759399P 1999-04-02 1999-04-02
US60/127,593 1999-04-02

Publications (2)

Publication Number Publication Date
WO2000059488A2 WO2000059488A2 (en) 2000-10-12
WO2000059488A3 true WO2000059488A3 (en) 2001-03-01

Family

ID=22430904

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/008524 WO2000059488A2 (en) 1999-04-02 2000-03-31 Enhanced tissue and subcellular delivery of vitamin e compounds

Country Status (4)

Country Link
EP (1) EP1169033A2 (en)
AU (1) AU4053700A (en)
CA (1) CA2366884A1 (en)
WO (1) WO2000059488A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080038316A1 (en) 2004-10-01 2008-02-14 Wong Vernon G Conveniently implantable sustained release drug compositions
US8541413B2 (en) 2004-10-01 2013-09-24 Ramscor, Inc. Sustained release eye drop formulations
US9993558B2 (en) 2004-10-01 2018-06-12 Ramscor, Inc. Sustained release eye drop formulations
EP2452670A1 (en) * 2004-10-01 2012-05-16 Ramscor, Inc. Conveniently implantable sustained release drug compositions
CZ300305B6 (en) * 2005-12-20 2009-04-15 Heaton, A. S. Pharmaceutical composition containing taxane derivative and exhibiting enhanced therapeutic efficiency
WO2008031171A1 (en) * 2006-09-15 2008-03-20 Univ Griffith Pro-oxidant anti-cancer compounds

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987002219A1 (en) * 1985-10-15 1987-04-23 The Liposome Company, Inc. Alpha tocopherol-based vesicles
WO1989003679A1 (en) * 1987-10-19 1989-05-05 The Liposome Company, Inc. Aqueous preparation of liposome composition
US5198432A (en) * 1988-01-29 1993-03-30 Center For Innovative Technology Method of preventing chlorohydrocarbon toxicity using sterol derivatives
WO1998030205A1 (en) * 1997-01-07 1998-07-16 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
WO1999004787A1 (en) * 1997-07-26 1999-02-04 West Pharmaceutical Services Drug Delivery & Clinical Research Centre Limited Taxol emulsion
JPH11335284A (en) * 1998-05-21 1999-12-07 Isehan:Kk Retinoid-containing skin lotion

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987002219A1 (en) * 1985-10-15 1987-04-23 The Liposome Company, Inc. Alpha tocopherol-based vesicles
WO1989003679A1 (en) * 1987-10-19 1989-05-05 The Liposome Company, Inc. Aqueous preparation of liposome composition
US5198432A (en) * 1988-01-29 1993-03-30 Center For Innovative Technology Method of preventing chlorohydrocarbon toxicity using sterol derivatives
WO1998030205A1 (en) * 1997-01-07 1998-07-16 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
WO1999004787A1 (en) * 1997-07-26 1999-02-04 West Pharmaceutical Services Drug Delivery & Clinical Research Centre Limited Taxol emulsion
JPH11335284A (en) * 1998-05-21 1999-12-07 Isehan:Kk Retinoid-containing skin lotion

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Week 200010, Derwent World Patents Index; AN 2000-109319, XP002156149 *
FARISS ET AL.: "Protection against carbon tetrachloride-induced hepatotoxicity by pretreating rats with the hemisuccinate esters of tocopherol and cholesterol", ENVIRON. HEALTH PERSPECT., vol. 101, no. 6, November 1993 (1993-11-01), pages 528 - 536, XP000972287 *
FARISS: "The selective antiproliferative effects of alpha-tocopheryl hemisuccinate and cholesteryl hemisuccunate on murine leukemia cells result form the action of the intact compounds", CANCER RES., vol. 54, no. 13, 1 July 1994 (1994-07-01), pages 3346 - 3351, XP000965041 *
SHIEH ET AL.: "Liposomal delivery system for taxol", J. FERMENTATION BIOENGINEERING, vol. 83, no. 1, 1997, pages 87 - 90, XP000965160 *
TIRMENSTEIN: "Administration of the Tris salt of alpha-tocopheryl hemisuccinate inactivates CYP2E1, enhances microsomal alpha-tocopherol levels and protecst agianst carbon tetrachloride-induced hepatotoxicity", FREE RADICAL BIOLOGY MEDICINE, vol. 26, no. 7-8, April 1999 (1999-04-01), pages 825 - 835, XP000965056 *

Also Published As

Publication number Publication date
WO2000059488A2 (en) 2000-10-12
AU4053700A (en) 2000-10-23
CA2366884A1 (en) 2000-10-12
EP1169033A2 (en) 2002-01-09

Similar Documents

Publication Publication Date Title
WO2004111192A3 (en) Targeted delivery to legumain-expressing cells
PL351280A1 (en) Methods and compositions for treating solid tumors
AU2274201A (en) Compounds and compositions for delivering active agents
HK1102991A1 (en) Pharmaceutical formulation of decitabine
WO2004045523A3 (en) Combination administration of an indolinone with a chemotherapeutic agent for cell proliferation disorders
WO2001080843A3 (en) Inhibition of abnormal cell proliferation with camptothecin and combinations including the same
MXPA01008611A (en) Compounds and compositions for delivering active agents.
GB0122318D0 (en) Organic compounds
CA2418862A1 (en) Antioxidants in clusters of structured water
CA2505128A1 (en) Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases
MXPA04006039A (en) Methods for the treatment of peripheral neural and vascular ailments.
WO2001062300A3 (en) Caspase activated prodrugs therapy
MY134422A (en) Platinum derivative pharmaceutical formulations.
CA2390295A1 (en) A method for chemoprevention of prostate cancer
WO2009073050A3 (en) Use of curcumin to block brain tumor formation in vivo
CA2485535A1 (en) Modified release pharmaceutical formulation
AR011133A1 (en) CONTROLLED RELEASE MICROGRANULES CONTAINING CISPLATINE, PROCEDURE FOR ITS PREPARATION, PHARMACEUTICAL COMPOSITION AND USE IN THE MANUFACTURE OF A POLYCHIMOTHERAPY MEDICATION OR IN ASSOCIATION WITH RADIOTHERAPY.
WO2005004808A3 (en) TETRACYCLIC COMPOUNDS AS c-MET INHIBITORS
WO2001074376A3 (en) Cathepsin inhibitors in cancer treatment
WO2006124033A3 (en) Compositions and methods for reduction of cutaneous photoageing
WO2000059488A3 (en) Enhanced tissue and subcellular delivery of vitamin e compounds
WO2009019708A3 (en) Pharmaceutical compositions and methods for the treatment of cancer
CA2383224A1 (en) Extracts of orange peel for prevention and treatment of cancer
MX2010003594A (en) Crystalline forms of dmxaa sodium salt.
IL154755A0 (en) Antitumor theraphy comprising distamycin derivatives

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref document number: 2366884

Country of ref document: CA

Ref country code: CA

Ref document number: 2366884

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2000919928

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09937895

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2000919928

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2000919928

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)